Evidence map›Paper›PMID 30338489›Full record

ReviewPsychopharmacology2019

Synthetic cathinone adulteration of illegal drugs.

Chicora F Oliver, Joseph J Palamar, Alberto Salomone, Steven J Simmons, Helene L Philogene-Khalid, Nick Stokes-McCloskey, Scott M Rawls

Abstract readReview
In one paragraph

Review in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. A critical review of workplace drug testing methods for old and new psychoactive substances: Gaps, advances, and perspectives.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Tusi: a new ketamine concoction complicating the drug landscape.The American journal of drug and alcohol abuse · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Interpol Review of Drug Analysis 2019-2022.Forensic science international. Synergy · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chicora F OliverCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, 882A, Philadelphia, PA, 19140, USA. chicoraoliver@temple.edu.ORCID http://orcid.org/0000-0003-1041-3100
Joseph J PalamarDepartment of Population Health, 180 Madison Avenue Room 1752, New York, NY, 10016, USA.
Alberto SalomoneCentro Regionale Antidoping "A. Bertinaria", Regione Gonzole 10/1, 10043, Orbassano, Torino, Italy.
Steven J SimmonsCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, 882A, Philadelphia, PA, 19140, USA.
Helene L Philogene-KhalidCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, 882A, Philadelphia, PA, 19140, USA.
Nick Stokes-McCloskeyCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, 882A, Philadelphia, PA, 19140, USA.
Scott M RawlsCenter for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, 882A, Philadelphia, PA, 19140, USA.

Funding

Pilot Projects Core (PPC)P30DA013429 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI SCOTT M. RAWLS · 2000 to 2026
$34.6M
TRAINING PROGRAM: DRUGS OF ABUSE RELATED NEUROPEPTIDEST32DA007237 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI ELLEN M UNTERWALD · 1988 to 2026
$10.6M
Training Program in Neurodevelopmental DisabilitiesT32NS007413 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI AMELIA J EISCH, ERIC D MARSH · 1998 to 2026
$8.9M
Psychoactive bath salts and the glutamate systemR01DA039139 · NIDA · TEMPLE UNIV OF THE COMMONWEALTH · PI RAWLS, SCOTT M. · 2015 to 2019
$1.8M
Development of a Rapid Survey to Detect Use of New and Emerging DrugsK01DA038800 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PALAMAR, JOSEPH J · 2015 to 2019
$879k
Chemokine Modulation of Psychostimulant-induced Behavior and NeuroplasticityF99NS105218 · NINDS · TEMPLE UNIV OF THE COMMONWEALTH · PI OLIVER, CHICORA F · 2018 to 2018
$19k
National Institute of Neurological Disorders and Stroke F99NS105218National Institute of Neurological Disorders and Stroke T32NS007413National Institute on Drug Abuse K01DA038800National Institute on Drug Abuse R01 DA039139National Institute on Drug Abuse T32DA007237NIDA NIH HHS K01 DA038800NIDA NIH HHS P30 DA013429NIDA NIH HHS R01 DA039139NIDA NIH HHS T32 DA007237NINDS NIH HHS F99 NS105218NINDS NIH HHS T32 NS007413
6 · The paper itself

Abstract

rationaleCurrent prevalence estimates of synthetic cathinone ("bath salt") use may be underestimates given that traditional metrics (e.g., surveys, urinalysis) often fail to capture the emergent issue of synthetic cathinone adulteration of more common illegal drugs, such as ecstasy (3,4-methylenedioxymethamphetamine).

objectivesThis review examines the evolution of synthetic cathinones and prevalence of use over the past decade in the United States. We also review methods of self-report and biological testing of these compounds as well as adverse outcomes associated with adulterated drug use.

resultsSynthetic cathinone use emerged in the United States by 2009 with use associated with tens of thousands of poisonings. Reported poisonings and self-reported use have substantially decreased over the past five years. However, our review suggests that current estimates of use are underestimates due to underreporting stemming primarily from unknown or unintentional use of adulterated formulations of relatively popular illegal drugs, such as ecstasy.

conclusionsWhile intentional synthetic cathinone use has decreased in recent years, evidence suggests that prevalence of use is underestimated. Testing of drugs and/or biological specimens can improve the accuracy of synthetic cathinone use estimates. Furthermore, we advocate that researchers and clinicians should become better aware that exposure to these potent compounds (e.g., as adulterants) often occurs unknowingly or unintentionally. To improve our understanding of synthetic cathinone adulteration, research utilizing a combinatorial approach (survey and biological testing) will help more accurately estimate the prevalence and impact of this public health issue.

Indexed as

AlkaloidsCentral Nervous System StimulantsDrug ContaminationHumansIllicit DrugsN-Methyl-3,4-methylenedioxyamphetaminePoison Control CentersPrevalenceSelf ReportSubstance-Related DisordersSurveys and QuestionnairesSynthetic DrugsUnited StatesAlkaloidscathinoneCentral Nervous System StimulantsIllicit DrugsN-Methyl-3,4-methylenedioxyamphetamineSynthetic DrugsAddictionAdulterationEcstasyNovel psychoactive substancesSynthetic cathinones

Identifiers

PMID30338489
PMCPMC6472990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.